233 related articles for article (PubMed ID: 25843460)
1. [Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer].
Matsuyama S; Kuramoto T; Tanaka R; Hashiguchi K
Nihon Shokakibyo Gakkai Zasshi; 2015 Apr; 112(4):714-20. PubMed ID: 25843460
[TBL] [Abstract][Full Text] [Related]
2. Ileal perforation following cetuximab and FOLFIRI chemotherapy in a patient with ascending colon cancer with peritoneal carcinomatosis.
Kim YW
J BUON; 2017; 22(3):804-805. PubMed ID: 28730797
[No Abstract] [Full Text] [Related]
3. [Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab].
Masuishi T; Muro K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():587-91. PubMed ID: 25831828
[No Abstract] [Full Text] [Related]
4. [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Toyokawa A; Nakajima T; Inui K; Yamashita H; Gon H; Kanemitsu K; Tanaka K; Tsukamoto T; Hamabe Y; Ishida T
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1167-9. PubMed ID: 19620810
[TBL] [Abstract][Full Text] [Related]
5. [A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
Kadota T; Osuga T; Ogawa H; Kitami M; Ishimura M; Shigaki Y; Nakajima E; Nakata S; Kadota C; Hirano S; Ikura Y; Iwai Y; Yoshikawa T; Ueno N; Tamura T
Nihon Shokakibyo Gakkai Zasshi; 2014 Jan; 111(1):115-23. PubMed ID: 24390266
[TBL] [Abstract][Full Text] [Related]
6. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
7. [Standard chemotherapy for colonic neoplasms].
Hyodo I
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
[No Abstract] [Full Text] [Related]
8. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
9. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
[No Abstract] [Full Text] [Related]
10. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
11. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Boisdron-Celle M; Metges JP; Capitain O; Adenis A; Raoul JL; Lecomte T; Lam YH; Faroux R; Masliah C; Poirier AL; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):24-33. PubMed ID: 28395759
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Fatal Interstitial Pneumonia during FOLFIRI plus Cetuximab Therapy for Liver Metastasis of Colon Cancer].
Aoyagi H; Ito H; Higuchi K; Koseki K; Watanabe I; Tanaka Y; Suzuki K; Nishi N; Nihei Z; Ito M
Gan To Kagaku Ryoho; 2018 Jan; 45(1):51-53. PubMed ID: 29362307
[TBL] [Abstract][Full Text] [Related]
14. [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
Ando M; Nagahama T; Fukuda A; Ami K; Kurokawa T; Hataji K; Ganno H; Kawasaki N; Arai K; Okada Y; Tei S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2288-90. PubMed ID: 21224550
[TBL] [Abstract][Full Text] [Related]
15. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan.
Oztop I; Demirkan B; Yaren A; Tarhan O; Sengul B; Ulukus C; Akin D; Sen M; Yilmaz U; Alakavuklar M
Tumori; 2004; 90(5):514-6. PubMed ID: 15656341
[TBL] [Abstract][Full Text] [Related]
16. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
17. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
[TBL] [Abstract][Full Text] [Related]
19. [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Goto A; Suzuki K; Hasegawa Y; Sukawa Y; Fujii K; Nishimura S; Yonezawa K; Abe T; Shinomura Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):169-71. PubMed ID: 20087056
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Aroldi F; Zaniboni A
Recenti Prog Med; 2015 Dec; 106(12):653e-6e. PubMed ID: 26780078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
